Study guide
12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants
APMLE Part I Basic Sciences Podiatry
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Lower Extremity Osteology
1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics
2 Chapter 2: Lower Extremity Arthrology & Ligaments
2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics
3 Chapter 3: Lower Extremity Myology & Compartments
3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations
4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy
4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces
5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods
5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines
6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology
6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods
7 Chapter 7: General & Cellular Pathology
7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors
8 Chapter 8: Systemic & Podiatric Pathology
8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation
9 Chapter 9: Organ-System Pathology
9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology
10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology
10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology
11 Chapter 11: Antimicrobial & Podiatric Therapeutics
11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology
12 Chapter 12: Systemic Pharmacology
12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents
13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy
13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways
14 Chapter 14: Histology, Integument, Embryology & Genetics
14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging
15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology
15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics
16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood
16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology
17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling
17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction
18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition
18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals
12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants
Key Takeaways Explain This Topic AI
Methotrexate inhibits dihydrofolate reductase and is dosed once weekly; daily dosing errors have been fatal, and folic acid reduces mucositis, cytopenias and liver toxicity.
Latent tuberculosis must be excluded before TNF inhibitors, which raise infection risk; JAK inhibitors carry boxed warnings for serious infection, malignancy, major cardiovascular events and thrombosis.
The 2022 ACR/AAHKS perioperative guideline for elective joint replacement continues conventional DMARDs, withholds biologics so surgery falls at the end of the dosing cycle, and withholds JAK inhibitors for 3 days.
Calcineurin inhibitors (cyclosporine, tacrolimus) cause nephrotoxicity, hypertension and tremor and are CYP3A4 substrates; mTOR inhibitors impair wound healing.
Capecitabine and 5-fluorouracil cause hand-foot syndrome, EGFR inhibitors cause paronychia and periungual granulation tissue, and taxanes, vinca alkaloids and platinum agents cause peripheral neuropathy.
Last updated: October 2026
12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants
The pharmacology outline lists anti-inflammatories (DMARDs and biologics) and chemotherapeutic agents (antineoplastics, antirheumatics and immunosuppressants). Rheumatoid arthritis, psoriatic arthritis, organ transplantation and cancer are common in podiatric patients. These drugs affect infection risk, wound healing, surgical timing and the skin and nails of the foot.
Conventional Synthetic DMARDs
Drug Mechanism Monitoring and adverse effects
Methotrexate Inhibits dihydrofolate reductase ; at low weekly doses it also increases anti-inflammatory adenosine Given once weekly ; daily dosing errors have caused deaths. Folic acid supplementation; liver toxicity, cytopenias, pneumonitis, mucositis, teratogenic . TMP-SMX adds antifolate toxicity, and high-dose NSAIDs or PPIs can reduce methotrexate clearance
Hydroxychloroquine Raises endosomal pH and interferes with antigen processing and Toll-like receptor signaling Retinal toxicity : baseline and periodic eye examinations; QT effects
Sulfasalazine Metabolized to 5-aminosalicylate and sulfapyridine GI upset, reversible oligospermia, hemolysis in G6PD deficiency, sulfa hypersensitivity
Leflunomide Inhibits dihydroorotate dehydrogenase (pyrimidine synthesis) Hepatotoxicity, teratogenic with a very long half-life (cholestyramine washout)
Biologic and Targeted Synthetic DMARDs
Target Drugs Key cautions
TNF-alpha Infliximab (chimeric), adalimumab, etanercept (soluble receptor), certolizumab, golimumab Screen for latent TB and hepatitis B; serious infections; can worsen heart failure and demyelinating disease
IL-6 receptor Tocilizumab, sarilumab Suppresses CRP , so infection can be missed; GI perforation; lipid elevation
- T-cell costimulation Abatacept (CTLA-4-Ig blocks CD80/86) Infections
- CD20 (B cells) Rituximab Hepatitis B reactivation , PML, infusion reactions
- IL-1 Anakinra, canakinumab Sometimes used for refractory gout flares
IL-17 and IL-12/23 or IL-23 Secukinumab, ixekizumab; ustekinumab, guselkumab Psoriasis and psoriatic arthritis; IL-17 inhibitors can worsen inflammatory bowel disease and raise Candida risk
JAK kinases (targeted synthetic) Tofacitinib, baricitinib, upadacitinib Boxed warnings : serious infections (including herpes zoster), mortality, malignancy, major adverse cardiovascular events and thrombosis
Perioperative Management
The 2022 ACR/AAHKS guideline for elective hip and knee replacement in patients with rheumatic disease advises:
- Continue conventional DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine)
- Withhold biologics and time surgery for the end of the dosing interval
- Withhold JAK inhibitors for 3 days before surgery
- Restart once the wound is healing and no infection is present (often about 14 days)
Surgeons commonly apply these principles to elective foot and ankle surgery, coordinating with the patient's rheumatologist. Chronic corticosteroids are continued at the usual daily dose rather than stopped or given as routine stress doses.
Transplant and Other Immunosuppressants
Class Drugs Mechanism Key adverse effects
Calcineurin inhibitors Cyclosporine (binds cyclophilin), tacrolimus (binds FKBP12) Block calcineurin, so NFAT cannot drive IL-2 transcription Nephrotoxicity , hypertension, hyperkalemia , tremor; tacrolimus causes post-transplant diabetes; cyclosporine causes gingival hyperplasia and hirsutism. CYP3A4 substrates : azoles and macrolides raise levels, rifampin lowers them
mTOR inhibitors Sirolimus, everolimus FKBP12 complex inhibits mTOR, blocking the T-cell response to IL-2 Impaired wound healing , hyperlipidemia, mouth ulcers, pneumonitis
Antimetabolites Azathioprine (6-MP prodrug), mycophenolate (inhibits IMP dehydrogenase) Block purine synthesis in lymphocytes Myelosuppression ( TPMT/NUDT15 testing for azathioprine; allopurinol interaction , 11.3); mycophenolate is teratogenic and causes GI upset
Glucocorticoids Prednisone Broad transrepression Infection, hyperglycemia, osteoporosis, avascular necrosis, poor healing
- Costimulation blocker Belatacept CTLA-4-Ig variant Post-transplant lymphoproliferative disorder
- Antineoplastic Agents
Class Examples Mechanism Toxicities, emphasizing the foot
Alkylating agents Cyclophosphamide DNA cross-linking Hemorrhagic cystitis (acrolein; mesna prevents it), myelosuppression
Platinum agents Cisplatin, oxaliplatin, carboplatin DNA cross-links Peripheral neuropathy , nephrotoxicity and ototoxicity (cisplatin), cold-triggered dysesthesia (oxaliplatin)
Antimetabolites Methotrexate, 5-fluorouracil, capecitabine , gemcitabine Inhibit nucleotide synthesis (5-FU inhibits thymidylate synthase) Hand-foot syndrome (palmar-plantar erythrodysesthesia: painful erythema and blistering of the palms and soles), mucositis; DPD deficiency causes severe toxicity
Microtubule inhibitors Vincristine (blocks polymerization); paclitaxel, docetaxel (stabilize microtubules) Mitotic arrest Chemotherapy-induced peripheral neuropathy (stocking-glove), vincristine ileus, taxane nail changes and onycholysis
Anthracyclines Doxorubicin Intercalation, topoisomerase II inhibition, free radicals Cardiomyopathy (dexrazoxane protects); severe necrosis if extravasated
Topoisomerase inhibitors Etoposide (II), irinotecan (I) DNA strand breaks Myelosuppression; irinotecan diarrhea
Bleomycin Free-radical DNA cleavage Pulmonary fibrosis; intralesional use for warts (11.2)
Targeted kinase inhibitors Imatinib (BCR-ABL); EGFR inhibitors (erlotinib, cetuximab); multikinase inhibitors (sorafenib, sunitinib); BRAF plus MEK inhibitors Block oncogenic signaling EGFR inhibitors cause acneiform rash and paronychia with periungual pyogenic granuloma-like lesions ; multikinase inhibitors cause hand-foot skin reaction (painful hyperkeratosis at pressure points)
Immune checkpoint inhibitors Pembrolizumab, nivolumab, ipilimumab Release T-cell brakes Immune-related adverse events (6.5)
Tumor lysis syndrome (hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia) is prevented with hydration and allopurinol or rasburicase , which is contraindicated in G6PD deficiency.
Tip
In a patient receiving chemotherapy, burning feet with reduced vibration sense suggests chemotherapy-induced neuropathy. Painful erythema of the soles suggests hand-foot syndrome, and new painful periungual granulation tissue suggests an EGFR inhibitor effect. All three are managed with the oncology team and protective footwear, not by stopping the cancer drug on one's own.